** Shares of Regulus Therapeutics RGLS.O more than double to $7.79 premarket
** Novartis offers to buy Regulus for $7/shr cash upfront and another $7/shr on hitting certain regulatory milestones for kidney disease drug farabursen
** Offer worth $800 mln on upfront price
** RGLS shares have already more than doubled this year through last close
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。